DTE
52
-2
SWK
34
-2
AEP
62
-4
GWW
55
4
IP
33
8
KO
50
-2
FAST
34
2
FITB
38
2
KEY
22
2
XRX
34
-3
DE
46
-10
SCHW
34
11
NRG
39
4
HUM
77
4
OXY
49
-10
PPG
44
3
MDLZ
50
-5
PPL
52
2
WM
59
2
CMA
18
-3
DTE
52
-2
SWK
34
-2
AEP
62
-4
GWW
55
4
IP
33
8
KO
50
-2
FAST
34
2
FITB
38
2
KEY
22
2
XRX
34
-3
DE
46
-10
SCHW
34
11
NRG
39
4
HUM
77
4
OXY
49
-10
PPG
44
3
MDLZ
50
-5
PPL
52
2
WM
59
2
CMA
18
-3
Financhill
Back

Novo Nordisk A/S 10K Form

Buy
58

NVO
Novo Nordisk A/S

Last Price:
91.81
Seasonality Move:
5.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NVO News And Ratings

See the #1 stock for the next 7 days that we like better than NVO

NVO Financial Statistics

Sales & Book Value

Annual Sales: $25.09B
Cash Flow: $3.2B
Price / Cash Flow: 42.4
Annual Sales: $2.95
Price / Book: 30.87

Profitability

EPS (TTM): 2.10670
Net Income (TTM): $9.52B
Gross Margin: $21.05B
Return on Equity: 82.75%
Return on Assets: 27.17%

Novo Nordisk A/S Earnings Forecast

Key Novo Nordisk A/S Financial Ratios

  • The Gross Profit Margin over the past 39 years for NVO is 83.92%.
  • The Selling, General & Administrative Expenses for NVO have been equal to 28.64% of Gross Profit Margin.
  • The Research & Development expenses have been 13.59% of Revenue.
  • The Interest Expense is 0.68% of Operating Income.
  • The Net Earning history of NVO is 31.38% of Total Revenues.
  • Per Share Earnings over the last 39 years have been positive in 26 years.

Novo Nordisk A/S Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sector: Healthcare
Current Symbol: NVO
CUSIP: 670100
Website: novonordisk.com

Debt

Debt-to-Equity Ratio: 0.28
Current Ratio: 0.88
Quick Ratio: 0.68

Price-to-Earnings

Trailing P/E Ratio: 52.61
Forward P/E Ratio: 37.41

NVO Technical Analysis vs Fundamental Analysis

Buy
58
Novo Nordisk A/S (NVO) is a Buy

Is Novo Nordisk A/S a Buy or a Sell?

  • Novo Nordisk A/S stock is rated a Buy
    The current Novo Nordisk A/S [NVO] share price is $91.13. The Score for NVO is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.